MediFind
Condition

Hemophilia A

Symptoms, Doctors, Treatments, Research & More

Condition 101

What is the definition of Hemophilia A?

Hemophilia A is a hereditary bleeding disorder caused by a lack of blood clotting factor VIII. Without enough factor VIII, the blood cannot clot properly to control bleeding.

What are the alternative names for Hemophilia A?

Factor VIII deficiency; Classic hemophilia; Bleeding disorder - hemophilia A

What are the causes for Hemophilia A?

When you bleed, a series of reactions take place in the body that helps blood clots form. This process is called the coagulation cascade. It involves special proteins called coagulation, or clotting, factors. You may have a higher chance of excess bleeding if one or more of these factors are missing or are not functioning like they should.

Factor VIII (eight) is one such coagulation factor. Hemophilia A is the result of the body not making enough factor VIII.

Hemophilia A is caused by an inherited X-linked recessive trait, with the defective gene located on the X chromosome. Females have two copies of the X chromosome. So if the factor VIII gene on one chromosome does not work, the gene on the other chromosome can do the job of making enough factor VIII.

Males have only one X chromosome. If the factor VIII gene is missing on a boy's X chromosome, he will have hemophilia A. For this reason, most people with hemophilia A are male.

If a woman has a defective factor VIII gene, she is considered a carrier. This means the defective gene can be passed down to her children. Boys born to such women have a 50% chance of having hemophilia A. Their daughters have a 50% chance of being a carrier. All female children of men with hemophilia carry the defective gene. Risk factors for hemophilia A include:

  • Family history of bleeding
  • Being male

What are the symptoms for Hemophilia A?

Severity of symptoms vary. Prolonged bleeding is the main symptom. It is often first seen when an infant is circumcised. Other bleeding problems usually show up when the infant starts crawling and walking.

Mild cases may go unnoticed until later in life. Symptoms may first occur after surgery or injury. Internal bleeding may occur anywhere.

Symptoms can include:

  • Bleeding into joints with associated pain and swelling
  • Blood in the urine or stool
  • Bruising
  • Gastrointestinal tract and urinary tract bleeding
  • Nosebleeds
  • Prolonged bleeding from cuts, tooth extraction, and surgery
  • Bleeding that starts without cause

What are the current treatments for Hemophilia A?

Treatment includes replacing the missing clotting factor. You will receive factor VIII concentrates. How much you get depends on:

  • Severity of bleeding
  • Site of bleeding
  • Your weight and height

Mild hemophilia may be treated with desmopressin (DDAVP). This medicine helps the body release factor VIII that is stored within the lining of blood vessels.

To prevent a bleeding crisis, people with hemophilia and their families can be taught to give factor VIII concentrates at home at the first signs of bleeding. People with severe forms of the disease may need regular preventive treatment.

DDAVP or factor VIII concentrate may also be needed before having dental extractions or surgery.

You should get the hepatitis B vaccine. People with hemophilia are more likely to get hepatitis B because they may receive blood products.

Some people with hemophilia A develop antibodies to factor VIII. These antibodies are called inhibitors. The inhibitors attack factor VIII so that it no longer works. In such cases, a man-made clotting factor called VIIa can be given.

What are the support groups for Hemophilia A?

You can ease the stress of illness by joining a hemophilia support group. Sharing with others who have common experiences and problems can help you not feel alone.

What is the outlook (prognosis) for Hemophilia A?

With treatment, most people with hemophilia A are able to lead a fairly normal life.

If you have hemophilia A, you should have regular checkups with a hematologist.

What are the possible complications for Hemophilia A?

Complications may include:

  • Long-term joint problems, which may require a joint replacement
  • Bleeding in the brain (intracerebral hemorrhage)
  • Blood clots due to treatment

When should I contact a medical professional for Hemophilia A?

Call your provider if:

  • Symptoms of a bleeding disorder develops
  • A family member has been diagnosed with hemophilia A
  • You have hemophilia A and you plan to have children; genetic counseling is available

How do I prevent Hemophilia A?

Genetic counseling may be recommended. Testing can identify women and girls who carry the hemophilia gene. Identify women and girls who carry the hemophilia gene.

Testing can be done during pregnancy on a baby in the mother's womb.

Blood

REFERENCES

Carcao M, Moorehead P, Lillicrap D. Hemophilia A and B. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 135.

Scott JP, Flood VH. Hereditary clotting factor deficiencies (bleeding disorders). In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 503.

Top Global Doctors

JO
Elite
Johannes Oldenburg
Bonn, NW, DE
FP
Elite
Flora Peyvandi
IT
AI
Elite
Alfonso M. Iorio
Hamilton, ON, CA
MS
Elite
Midori Shima
Kashihara-shi, 29, JP

Latest Research

Latest Advance
Study
  • Condition: Severe hemophilia A
  • Journal: Annals of hematology
  • Treatment Used: Two Extended Half-Life PEGylated Recombinant FVIII Products
  • Number of Patients: 18
  • Published —
This study compared two extended half-life PEGylated recombinant FVIII products in patients with severe hemophilia A.
Latest Advance
Study
  • Condition: Hemophilia A
  • Journal: Journal of thrombosis and haemostasis : JTH
  • Treatment Used: N8-GP
  • Number of Patients: 68
  • Published —
This study tested the safety and efficacy of using N8-GP to treat patients with hemophilia A.

Clinical Trials

Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 40
  • Start Date: March 2021
Prospective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia A